Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Clinical trials suggest that psilocybin — the active ingredient in magic mushrooms — can provide durable remission from an increasingly common mental health condition.
Some researchers are finding clues that MDMA might be able to treat post-traumatic stress disorder. But the science has yet to catch up with the optimism.
Personalizing cancer treatment doesn’t only mean matching a drug to molecular markers on a tumour — it should also take into account a person’s sexual identity, interests and wishes.
Urological oncologist Miguel Ángel Jiménez-Ríos explains how the psychological burden of the disease should change physicians’ approach to treatment and outreach.
Prostate-specific antigen is an established biomarker, but it is flawed. Research into alternatives is starting to get results, but will they reduce mortality?
Hormonal therapy has helped many people with prostate cancer to live longer, fuller lives, but mounting evidence suggests that the drugs drive or exacerbate cardiovascular problems.
Advances in the ability to find and treat tumours that have spread around the body are changing the perception of what is possible for people with advanced disease.
Despite success against other cancers, prostate tumours have so far resisted treatment with immunotherapy. But some researchers are persisting with the approach.